HOWL News and Press, Werewolf Therapeutics Inc. From 08/10/23

2023-08-10 10:32:34 ET Werewolf Therapeutics press release ( NASDAQ: HOWL ): Q2 GAAP EPS of -$0.14 beats by $0.27 . Revenue of $8.08M (+94.7% Y/Y) beats by $4.93M . For further details see: Werewolf Therapeutics GAAP EPS of -$0.14 beats by $0.27, revenue ...

- Phase 1/1b clinical trial for IL-2 INDUKINE™ WTX-124 progressing in patients with advanced or metastatic solid tumors; initial first-in-human clinical data from monotherapy dose-escalation arm expected in 4Q 2023 - - Phase 1 clinical trial for IL-12 INDUKINE WTX-330 progressing...

2023-08-01 15:49:41 ET Summary MDNA failed to report data from the fifth dosing cohort, of its phase 1/2 ABILITY study of MDNA11, in Q2'23 as expected. The company is instead presenting data from both the fifth and sixth cohorts of the trial on August 9, 2023. MDNA has cash to...

2023-06-06 12:13:19 ET Jefferies issued a Buy rating on Werewolf Therapeutics ( NASDAQ: HOWL ) on Tuesday, citing an attractive valuation in the cancer-focused biotech ahead of a data readout scheduled in Q4 2023 for WTX-124, one of its lead candidates. WTX-124 is a conditionall...

WATERTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body...

- Progressing Phase 1/1b clinical trial for IL-2 INDUKINE WTX-124 in advanced or metastatic solid tumors; initial first-in-human clinical data from monotherapy dose-escalation arm expected in 4Q 2023 - - Progressing Phase 1 clinical trial for IL-12 INDUKINE WTX-330 in patients with advanc...

WATERTOWN, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body ...

WATERTOWN, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics, announced the publication in Can...

2023-03-23 07:15:50 ET Werewolf Therapeutics press release ( NASDAQ: HOWL ): Q4 GAAP EPS of -$0.39 beats by $0.16 . Revenue of $7.28M beats by $5.21M . As of December 31, 2022, cash and cash equivalents were $129.3 million, compared to $157.5 million as of...

– Initial first-in-human clinical data for IL-2 INDUKINE WTX-124 monotherapy expected in 4Q 2023 from Phase 1/1b clinical trial in advanced or metastatic solid tumors – – Dosed first patient in Phase 1 clinical trial evaluating IL-12 INDUKINE WTX-330 in patient...